REPORT DO	OCUMENTATION F	PAGE	Form Approved OMB No. 0704-0188
dathering and maintaining the data needed, and	completing and reviewing the collection of for reducing this burgen, to Washington H	f information. Send comments reg eadquarters Services, Directorate f	reviewing instructions, searching data source arding this burden estimate or any other aspect of the or information Operations and Reports, 1215 setters oper (0704-0188), washington, DC 20503.
1. AGENCY USE ONLY (Leave bland			D DATES COVERED
4 STITLE AND SUBTITLE		/ ///////	S. FUNDING NUMBERS
<sup>7</sup> A Prototype Diagno Infectious Disease			ELECTE C
Omar Bouhaddou Homer Warner, J	r.		MAR 1 5 1991 H 3
PERFORMING ORGANIZATION NA Applied Informa 295 Chipeta Way Salt Lake City,	tics, Inc.		8. PERFORMING ORGANIZATION REPORT NUMBER
. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESS(E	S)	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
U. S. Army Research O P. O. Box 12211	ffice		AGENCY REPORT NUMBER
Research Triangle Par	k, NC 27709-2211		ARU 27544.1-MA
The view, opinions an			
The view, opinions an author(s) and should position, policy, or 2a. DISTRIBUTION/AVAILABILITY S	not be construed as decision, unless so TATEMENT	an official Depa designated by ot	rtment of the Army
author(s) and should	not be construed as decision, unless so TATEMENT	an official Depa designated by ot	rtment of the Army her documentation.
The view, opinions an author(s) and should <u>position</u> , <u>policy</u> , or 12a. DISTRIBUTION/AVAILABILITY S Approved for public r Approved for public r This contract infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic o Iliad program develop knowledge base cont	not be construed as <u>decision, unless so</u> TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Informati ains over 1,090 diseases	an official Depa designated by ot unlimited. t of a prototype diagr United-States but pre onstrate the feasibility nedical expertise abo unced with the use of isease agent for study cal expert system use ics and the University and 5,600 disease ma	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all
The view, opinions an author(s) and should <u>position, policy, or</u> 12a. DISTRIBUTION/AVAILABILITY S Approved for public r Approved for public r Approved for public r Approved for public r II ABSTRACT (Maximum 200 words This contract infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic Iliad program develop knowledge base cont of the domains of inte problem-solving skill After complet	not be construed as <u>decision</u> , unless so TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Information ains over 1,090 diseases ernal medicine. The prima s and provide a wide range	an official Depa designated by ot unlimited. t of a prototype diagr United-States but pre onstrate the feasibility nedical expertise abo unced with the use of isease agent for study cal expert system use ics and the University and 5,600 disease ma try focus of Iliad is to ge and variety of sim ct, the Iliad prototype	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all o teach and test clinical ulated patient cases.
The view, opinions an author(s) and should <u>position, policy, or</u> 12a. DISTRIBUTION/AVAILABILITY S Approved for public r Approved for public r Approved for public r infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic of Iliad program develop knowledge base conto of the domains of inte problem-solving skill After complet operational and the fu	not be construed as <u>decision</u> , unless so TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Information ains over 1,090 diseases rnal medicine. The prima s and provide a wide range	an official Depa designated by ot unlimited. t of a prototype diagr United-States but pre onstrate the feasibility nedical expertise abo unced with the use of isease agent for study cal expert system use ics and the University and 5,600 disease ma try focus of Iliad is to ge and variety of sim ct, the Iliad prototype	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all b teach and test clinical ulated patient cases.
The view, opinions an author(s) and should <u>position, policy, or</u> 12a. DISTRIBUTION/AVAILABILITY S Approved for public r Approved for public r Approved for public r Approved for public r II ABSTRACT (Maximum 200 words This contract infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic Iliad program develop knowledge base cont of the domains of inte problem-solving skill After complet	not be construed as <u>decision, unless so</u> TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Information ains over 1,090 diseases ernal medicine. The prima s and provide a wide range ion of this one year proje rst performance tests are	an official Depa designated by ot unlimited. t of a prototype diagr United-States but pre onstrate the feasibility nedical expertise abo unced with the use of isease agent for study cal expert system use ics and the University and 5,600 disease ma try focus of Iliad is to ge and variety of sim ct, the Iliad prototype	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all teach and test clinical ulated patient cases. e for Q fever is 15. NUMBER OF PAGES 24
The view, opinions an author(s) and should <u>position</u> , <u>policy</u> , or 12a. DISTRIBUTION/AVAILABILITY S Approved for public r 13 ABSTRACT (Maximum 200 words This contract infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic Iliad program develop knowledge base cont of the domains of inte problem-solving skill After complet operational and the fin 4. SUBJECT TERMS Medical expert sy Infectious Diseas	not be construed as <u>decision, unless so</u> TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Information ains over 1,090 diseases rmal medicine. The prima s and provide a wide range ion of this one year projects rest performance tests are	an official Depa designated by ot n unlimited. t of a prototype diagr United-States but pre- onstrate the feasibility nedical expertise abo anced with the use of isease agent for study cal expert system use and the University and 5,600 disease ma try focus of Iliad is to ge and variety of sim ct, the Iliad prototype encouraging.	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all b teach and test clinical ulated patient cases. e for Q fever is 15. NUMBER OF PAGES 24 16. PRICE CODE
The view, opinions an author(s) and should <u>position, policy, or</u> 12a. DISTRIBUTION/AVAILABILITY S Approved for public r 13 ABSTRACT (Maximum 200 words This contract infectious diseases w countries. The purpos envisioned to operate might be scarce and t system. Qfever was se prototype diagnostic Iliad program develop knowledge base cont of the domains of inte problem-solving skill After complet operational and the fin subject TERMS Medical expert sy Infectious Diseas	not be construed as <u>decision, unless so</u> TATEMENT release; distribution aimed at the developmen hich might be rare in the se of this work is to demo in remote places where r he handling of cases enha elected as the infectious d expert system. The medi ped by Applied Information ains over 1,090 diseases ernal medicine. The prima s and provide a wide range ion of this one year proje rst performance tests are	an official Depa designated by ot unlimited. t of a prototype diagr United-States but pre onstrate the feasibility nedical expertise abo unced with the use of isease agent for study cal expert system use ics and the University and 5,600 disease ma try focus of Iliad is to ge and variety of sim ct, the Iliad prototype	rtment of the Army her documentation. 12b. DISTRIBUTION CODE nostic expert system in evalent in foreign y of a prototype which is ut the rare diseases such a diagnostic expert ying the feasibility of a ed in this project is the y of Utah. Iliad's current anifestations across all teach and test clinical ulated patient cases. e for Q fever is 24 16. PRICE CODE CATION 20. L'IMITATION OF ABSTRAC

AD-A232 443

. 

# A Prototype Diagnostic Expert System in Rare Infectious Diseases Using Iliad and Qfever

**Final Report** 

by Omar Bouhaddou and Homer Warner Jr.

January 25, 1991

USARIID Contract # DAAL03-90-C-0001

Applied Informatics, Inc.

Approved for public release Distribution unlimited

91 2 15 201



THE VIEWS, OPINIONS, AND/OR FINDINGS CONTAINED IN THIS REPORT ARE THOSE OF THE AUTHOR(S) AND SHOULD NOT BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION, POLICY, OR DECISION, UNLESS SO DESIGNATED BY OTHER DOCUMENTATION.

## Table of Contents

Introduction	3
Development of a Prototype Diagnostic Expert System in Infectious Diseases	4
The knowledge Engineering Environment	4
The Qfever Prototype	
Temporal Aspects	
Video Link	
Transferability	6
Testing the Qfever Prototype	7
Prospects for the Future	
List of Scientific Personnel	8
Bibliography	9
Appendix A	
QFEVER DISEASE PROFILES	10
Appendix B	
ILIAD REFERENCES	17
List of Inventions	22

### Introduction

Today, knowledge-based systems constitute a new and exciting way to bring the best of medical knowledge to students, practitioners and patients. Expert systems applications have been implemented in a variety of settings. A few examples of medical expert systems include Iliad, HELP, DXplain, CARE and QMR, PUFF, Oncocyn, etc.(refs). The performance of these systems has been documented in the literature and judged at least as good as that of human experts. However, only a few have made it to the real world and are commercial available.

Today, the field and society at large need to know how artificial intelligence applications and expert systems in particular will make a difference in the real world. Thus, a major issue for developers of expert systems is to investigate practical applications of the technology. One interesting such application constitutes the substance of the collaboration between the USARIID and Applied Informatics. The collaboration aims at the development of a prototype diagnostic expert system in infectious diseases which might be rare in the United-States but prevalent in foreign countries. The purpose of this work is to demonstrate the feasibility of a prototype which is envisioned to operate in remote places where medical expertise about the rare diseases might be scarce and the handling of cases enhanced with the use of such a diagnostic expert system.

Qfever was selected as the infectious disease agent for studying the feasibility of a prototype diagnostic expert system. Qfever is a ricketsiella infectious disease which, although not lethal, causes severe morbidity. The chronic form of the disease may result from the primary infection and lead to cardiac and liver involvement. The medical expert system used in this project is the Iliad program developed by Applied Informatics and the University of Utah. Iliad's current knowledge base contains over 1090 diseases and syndromes across all of the domains of internal medicine. The primary focus of Iliad is to teach and test clinical problem-solving skills and provide a wide range and variety of simulated patient cases.

The project started in January 1990. Phase 1 of the project describes the diagnostic criteria for Qfever using the literature, expert judgement and real patient cases. Phase 2 tests the performance of the prototype against real as well as simulated cases. Phases 1 and 2 repeat until a reliable performance evolves. Another validation measurement and refinement of the prototype was obtained through face-value evaluation of the medical logic by other experts in the field. Dr. Thomas Marrie from Nova Scotia was involved in critiquing the Qfever disease profiles we developed as well as in the validation study of the prototype based on a relatively large database of Qfever cases (188 cases).

After the one year duration of this work, the Iliad prototype for Q fever is operational and the first performance tests are encouraging. The temporal dimension of Qfever was modelled in Iliad using two clinically significant states of Qfever (i.e., early and late stages). These two states were deemed by medical experts as adequate to represent the different facets of the disease. Furthermore, a link to a database of digitized pictures has strengthened the educational value of the prototype expert system.

In the future, there needs to be further study of the reliability fo the current Qfever prototype. This would involve the abstracting of a large number of cases and a performance judgement of the Iliad prototype by independent experts. Field testing is the next level of testing. This level of evaluation is the study of the impact of Iliad on the judgement of nonexpert physicians. Field testing is also useful to collect data about the transferability of the program and the program's performance in different geographical locations. Finally, once this 'vertical' investigation of the first prototype is achieved with satisfactory results, the knowledge base is expanded to include new disease profiles. The more knowledge the system offers to its users the more useful and reliable the system will be.

## Development of a Prototype Diagnostic Expert System in Infectious Diseases

In general, the development a prototype diagnostic expert system starts with the definition of the knowledge domain and the intended audience. Rare infectious diseases is the knowledge of interest and Qfever is the specific agent selected to carry out our study. The task is then to develop a diagnostic model of the Qfever infection combining all available sources of information. The model would be tested in remote areas where Qfever infection is prevalent and the medical staff is not particularly familiar with the pathology.

#### The knowledge Engineering Environment

The process of knowledge engineering in Iliad refers to the sum of all activities that aim to capture, restructure and validate knowledge in a particular domain in order to build a computer representation of this knowledge for educational, training and testing purposes. In this section, we will give an overview of the different steps involved in the knowledge engineering process which is illustrated by the diagram below and refer to specific chapters in the knowledge engineering handbook for in depth information about each step (see Knowledge Engineering in Iliad: the Development Tools).



Figure 1: The knowledge engineering process in Iliad

The first step in knowledge engineering is the acquisition of knowledge from human experts. Knowledge is acquired through formal interview techniques with a medical domain expert which is facilitated by a knowledge engineering using computerized support tools in a quiet, comfortable setting.

Step 2, in the knowledge engineering process, is to match the free text terminology used during the frame development effort to coded vocabulary terms in the Knowledge Base Dictionary (KBD).

Once all the terms used in a knowledge frame have been defined in the KBD, the Frame Author program is used to create Iliad frames (step 3). The Frame Author converts the free text fo knowledge to a structured form in which every item is an item previously defined in the KBD.

The frames assembled with the Frame Author program are then checked before they can be compiled to run with Iliad. This is done in step 4 using the IliadUtilities program.

Once the pre-compilation checks have cleared, the BatchCompiler is used to compile the frames into the "Iliad files" folder (step 5).

Running Iliad to test the performance of the frames is the next step (step 6) in the knowledge engineering cycle. The knowledge engineering process cycles with many revisions to the knowledge base taking place before a reliable performance of the system evolves.

#### The Qfever Prototype

Qfever is the infectious disease agent selected to study the feasibility of a diagnostic expert system that will support military medical staff in remote areas. Qfever is a relatively rare disease in the US, but outbreaks have been reported all around the world. Serology testing (ELISA test) allows for the identification of offending agent: ricketsiella Coxiella Burnetii. The infectious condition, when recognized, has been treated with appropriate dosages of tetracyclin. However, the disease presentation is not very specific and is often confused with other pathologies (e.g., atypical pneumonia) and left untreated. A fraction of the acute Qfever infections develop into chronic Qfever with liver, and heart involvement.

Coxiella Burnetii is an aerosol and is thought to constitute a potential bacteriological weapon. However, in most cases, the infection was traced to animal carriers who do not suffer from any consequences. Specifically, Coxiella Burnetii can be contracted from animal's placenta, thus more prevalent in farmers, slaughter house personel, and infectious diseases laboratory personel.

The development of three major frames for Qfever: Qfever, (Early Stage), Qfever (Late Stage) and Blood Culture Negative Endocarditis were considered by experts in the domain to adequately cover the relevant distinction between the different phases of the disease. Appendix A includes the disease profiles of these three frames and the related intermediate disease-syndromes.

#### **Temporal Aspects**

The temporal aspect of an expert system refers to a set of capabilities that helps the system recognize and take advantage of time-oriented clinical events, such as the first value of a laboratory test, the value of a test after or before the occurrence of another event, and the identification of trends. This set of capabilities may help the expert system deal with disease stages and severities.

A natural way to incorporate temporal aspects into a decision support module is to tie the module to a live clinical database. The knowledge base could then be 'time-driven' as well as 'data-driven'.

Because Iliad is not tied to real-time patient database, the only way to a model a disease over time is to build a frame for each significant phase of the diagnostic process. Thus, in the Qfever example, domain experts have judged that a good approximation of the disease process is accomplished with two frames: one for the early or acute phase, and one for the late or chronic phase.

#### Video Link

Any disease or finding name in the Iliad knowledge base dictionary can be linked to available digitized pictures. At any point during a consultation session with Iliad, the user can access the pictorial representations to learn more about the diagnostic criteria or patient finding.

Iliad will append a "(p)" at the end of the text of a term to indicate the term has one or more pictures linked to it. Wherever a dictionary term appears in Iliad, as a patient finding or a workup suggestion, the user can select the term and activate the 'Video' command within the 'Browse' menu. Each picture comes with text describing the content of the picture. The textual description of a picture can include references to other pictures within the picture database, in which case, the name of the picture referenced is in bold.

Double clicking on the bold name will display the referenced picture in a 'Hyperpicture' fashion.

To access digitized pictures within Iliad, the knowledge engineer creates textual descriptions of the pictures and links each picture to one or more Iliad dictionary codes that they illustrate.

The hardware requirements for linking Iliad to digitized pictures are the same as for running Iliad plus a color monitor (e.g., MacII, MacSI) for adequate picture quality. A manual exists with instructions on how to create and link digitized pictures to Iliad (see Linking Digitized Pictures to Iliad).

#### Transferability

The term transferability in this context refers to the ability of the system's knowledge base to perform reliably in different geographical locations. Iliad's probabilistic knowledge representation models are particularly adaptable for reflecting geographical specificities. Indeed, the Bayesian model used by Iliad includes the a priori of a disease or of a diagnostic finding in its calculations. These frequencies can be estimated from a sample of the local population. Furthermore, Iliad allows for a site specific file where disease prevalences are stored and local knowledge is preserved.

Iliad's knowledge base development approach assumes there will only be one central site for maintaining the master knowledge base with each user site adding disease prevalence information. The central site will integrate feedback from all users into the master knowledge base file. Also, there are tools for producing and maintaining different versions of the expert system in multiple languages (e.g, French, English).

## **Testing the Qfever Prototype**

Testing of a diagnostic expert system encompasses process and outcome performance measures. These performance measures will validate the reliability of the knowledge base as well as the impact of the expert system on the outcome of the practice of its intended users.

This contract work did not include any study of outcome measures. The performance of the knowledge base was measured in several steps. First, a face-value evaluation of the disease descriptions was done by another infectious disease specialist (Dr. Thomas Marrie from Victoria General Hospital in Nova Scotia). Then, Dr. Larry Reimer from the University of Utah Medical Center, developer of the original infectious disease profiles, tested the behavior of the system using textbook examples, case reports in the literature and the simulation mode of Iliad. The simulation mode in Iliad allows for the generation of realistic patient cases from a disease profile. Generating patient cases from the expert system's knowledge base has been compared to the "Turing" test for medical expert system.

Finally, we are currently in the process of testing the performance of the system on 188 Qfever cases from Nova Scotia collected by Dr. Marrie. Tools for transferring data

from the large Nova Scotia database have been developed to facilitate the performance study of the prototype against real cases

## **Prospects for the Future**

The validation of the Qfever prototype against a large set of patient cases should enhance the reliability of the knowledge base. Another extension of this project would involve field testing the prototype in different geographical locations. To facilitate the transferability of the program, we added to the Iliad program the possibility to modify the content of the knowledge base to reflect geographical prevalence of disease. Finally, parallel efforts to the validation studies should aim to expand the knowledge base to include other rare infectious diseases. This would make interaction with the expert system more valuable. The personel of USARIID has been introduced to Iliad knowledge engineering techniques and familiarized with the knowledge development tools in order to facilitate the ongoing efforts of knowledge development and validation.

# List of Scientific Personnel that Participated in the development of the Qfever Prototype Expert System

Omar Bouhaddou, PhD	
Senior knowledge engineer at Applied Informatics	
Homer R. Warner, Jr.	
principal investigator and president of Applied of Informatics	
Homer R. Warner, MD, PhD	
professeur, chaiman of the department of medical informatics and	knowledge
engineer on the Iliad project	-
Dean K Sorenson, PhD	
biochemist and knowledge engineer on the Iliad project	
Stan Altman, MD	
hematologist and knowledge engineer on the Iliad project	
Larry Reimer, MD	
infectious diseases specialist and knowledge engineer on the Iliad	project
Thomas Marrie, MD	
infectious diseases specialist and consult int on the Qfever prototype	
Tim Cannon	
primary contact at the USARIID	
Glen Higbee	
principal investigator at the USARIID	

## Bibliography

- 1. Spelman WD. Q fever: a study of 111 consecutives cases (1982). Med J Aust;1:547-553
- 2. Powell OW. Q\_fever: clinical features. Australians Annals of Medicine. 9:214, 1960
- 3. Clark et al. Q Fever in California. Arch Int. Med. 88:155,1951
- 4. Field et al. Detection of C.burnetii. Journal of Infectious Diseases 148:477-487,1983
- 5. Safety and Immunogenecity of Q fever vaccin.reference from Tim cannon
- 6. Powell OW. Liver : olvement in Q fever. Australasian Annals of Medicine 1961;10:52-9.
- 7. Dr. Stan Altman (Hematologist expert working on the Iliad project at the University of Utah)
- 8. Dr. Thomas Marrie (Infectious Diseases expert working in Nova Scotia)
- 9. Dr. Larry Reimer (Infectious Diseases expert working on the Iliad project at the University of Utah)
- 10. Raoult et al. "Chronic Q ffever: diagnosis and follow up", Ann N w York Academy of sciences, 51-60
- 11. TS Marrie "A comparison of Qfever endocarditis with native valve endocarditis", Ann. New York Academy of sciences, 61-67
- 12. Iliad references (see Appendix B)

### **Appendix A: QFEVER DISEASE PROFILES**

A few guidelines on how to read the disease descriptions below: 1. The <u>disease name</u> appears at the top

2. the a priori represents the prevalence of the disease in the hospital (our hospitals)

3. the <u>findings</u> are either direct observations (e.g., historical, physical examinations, laboratory results) or a group of findings described in a sperate frame and indicated by an '@' sign.
4. <u>sensitivity</u> is the true positive rate = the fraction of patients with the disease that have with the finding.

5. <u>1</u> - specificity is the false positive rate = the fraction of patients without the disease that have with the finding.

Disease name: Q fever (early stage) A priori = .00003			
<pre>a. Temperature     &gt;38 and &lt; 40 C     &gt;= 40 C (104) b. @Atypical_Pneumonia (7)</pre>	.95 .52 (1) .51(5)	.15 .01 .015	
or @Non-specific symptoms of Q fever d. Hx of headache at retrobulbar area or	.90 .30 (3,10)	.20 .01	
Hx of headache or	.90 (2)	.15	
Hx of headache [with a specific quality] which is severe and frontal	.25	.03	
<pre>e. Sex, male g. Coxiella Burnetii ELISA is positive &gt;= 7 days of onset of symptoms</pre>	.85 .50 (4)	.57 .01	
or Coxiella Burnetii ELISA is positive 4 fold rise >= 7 days of onset of symptoms	.50 (4)	.001	
or Immunofluorescence shows Coxiella Burnetii antibody >= 15 days of onset of symptoms	.95 (4)	.01	
or Immunofluorescence shows Coxiella Burnetii antibody 4 fold rise >= 15 days of onset of symptoms or	.90 (4)	.001	
Complement fixation test shows >= 4 fold rise in phase II antibody titer to C. Burnetii >= 7 days of onset of symptoms or	.90 (2,3,4)	.001	
Complement fixation test shows phase II antibody titer > 1:128 to C. Burnetii >= 7 days of onset of symptoms g. Hx of contact with cattle, sheep, goats	.95 (2) .70	.001 .02	
or Hx of contact with sheep placenta or	.50	.001	
Hx of work in animal research facility housing sheep or	.20	.01	
Hx of contact with cats h. @Abnormal liver functions criteria for Q fever	.50 .65	.40 .05	
or PE shows hepatomegaly	.43(1,3,5,6)	.06	
or Liver tenderness (9)	.11(6)	.03	
or PE shows splenomegaly a priori: about 1 case / year	.10(10)	.01	

a priori: about 1 case / year

?confirm this before adding: cxr of multiple rounded opacities .95 (10) .--References 1. Spelman WD. Q fever: a study of 111 consecutives cases (1982). Med J Aust;1:547-553 2. Powell OW. Q fever: clinical features. Australians Annals of Medicine. 9:214, 1960 3. Clark et al. Q Fever in California. Arch Int. Med. 88:155,1951 4. Field et al. Detection of C.burnetii Journal of Infectious Diseases 148:477-487,1983 5. Safety and Immunogenecity of Q fever vaccin.reference from Tim cannon 6. Powell OW. Liver involvement in Q fever. Australasian Annals of Medicine 1961;10:52-8 7. a priori 8. Dr. Reimer 9. Dr. Altman 10. Dr. Thomas Marrie

#### Qfever Diagnostic Expert System-final report

Abnormal liver function criteria for Q fever

- a. SGOT u/mL
- b. SGPT u/mL
- c. alkaline phosphatase U/L d. Serum bilirubin mg/100mL

True if: a > 34 or b > 59 or c > 147 or d > 1.0

Qfever Diagnostic Expert System-final report

Non-specific symptoms of Q fever a. Hx of Abdominal pain b. Hx of sore eyes c. Hx of malaise/fatigue d. Hx of rash e. Hx of myalgia/weakness f. Hx of arthralgia g. Hx of nausea or/and vomiting h. Hx anorexia i. Hx of chest pain j. Hx of chills k. Hx of cough 1. Hx of weight loss > 5%m. PE shows clubbing n. Hx of back pain o. Hx of headache p. Hx of diarrhea q. @Anemia True if 6 of a-k and 4 of (1-q)References: 1. Dr. Larry Reimer 2. Raoult et al. "Chronic Q ffever: diagnosis and follow up", Ann. New York Academy of sciences, 51-60

3. TS Marrie "A comparison of Ofever endocarditis with native valve endocarditis", Ann. New York Academy of sciences, 61-67

Disease name: Q fever (late) A priori = .00001findings: sensitivity 1-specificity a. Hx of Q fever .80 (1) .001 or Hx of contact with cattle, sheep, goats .70 .02 or Hx of work in animal research facility .20 housing sheep .005 b. @Fever .90 .15 or @Non-specific symptoms of Q fever .50 .20 c. Sex, male .85 .57 e. @Abnormal liver functions criteria for Q fever .25 .05 or PE shows hepatomegaly .25 (2) .06 or PE shows splenomegaly .07 (2) .01 f. Complement fixation test shows phase I .001 .99 antibody titer > 1:128 to C. Burnetii h. @Culture-negative endocarditis .95 .0001

References: 1. Dr. Larry Reimer 2. Clarke, (see above references) 3. Dr.Thomas Marrie

a priori: about 1/3 y around here or about 1/100,000

Disease name: Culture-negative endocarditis A priori = .0001				
findings: sensitivity a. Heart murmur	1-specific .85	ity .10		
or definite change in murmur or new murmur or	.10	.001		
@Aortic insufficency or	.15	.0011		
@Mitral valve prolapse or	.29	.01		
Hx of mitral valve prolapse b. Blood culture positive for bacteria	.25 .0000001			
<pre>c. vegetations on heart valves   (echocardiography)</pre>	. 50	.02		
d. Hx of a heart valve replaced? or	.05	.002		
Hx of rheumatic fever e. @Infective embolic phenomena f. joint pains g. @Anemia of chronic disease	.20 .50 .33 .80	.01 .001 .10 .07		

References: 1. Dr. Larry Reimer 2. see also infective endocarditis

### **Appendix B: ILIAD REFERENCES**

- Anderson, CL, Warner HR. Iliad and Odyssey. Wheels for the Mind, Apple Computer Press, 1987.
- Bouhaddou O, Haug PJ, Warner HR. Use of the HELP clinical database to build and test medical knowledge. Proceedings of the 11th Symposium on Computer Applications in Medical Care, Washington DC, November 1987.
- DeJean D. Hope & glory: men, medicine, & PCs. PC Computing, pp. 70-72, September 1988.
- Fan C, Lincoln MJ, Haug PJ, Turner CW, Warner HR. ODYSSEY: A program to access medical knowledge. Proceedings of the 11th Symposium for Computer Applications in Medical Care, Washington DC, November 1987.
- Hukill MJ, Ward KM, Haug PJ, Warner HR. H.E.L.P. decision support on the Macintosh. Proceedings of the 11th Symposium for Computer Applications in Medical Care, Washington DC, November 1987.
- Lincoln MJ, Turner CW, Hesse B, Warner HR, Miller R. A comparison of clustered knowledge structures in Iliad and in Quick Medical Reference. Proceedings of the 12th Symposium for Computer Applications in Medical Care, Washington DC, November 1988.
- Sorenson D, Bouhaddou O, Wang W, Ben Said M, Canfield G, Fu L-S, Warner HR. Generation and maintenance of ILIAD medical knowledge in a HyperCard environment. Proceedings of the 12th Symposium for Computer Applications in Medical Care, Washington DC, November 1988.
- Yu H, Haug PJ, Lincoln MJ, Turner CW, Warner HR. Clustered knowledge representation: Increasing the reliability of computerized expert systems. Proceedings of the 12th Symposium for Computer Applications in Medical Care, Washington DC, November 1988.
- Bouhaddou O, Lepage E, Warner H Jr, Warner HR. An approach to evaluating the completeness of a medical knowledge base. Proceedings of the 13th Symposium on Computer Applications in Medical Care. Washington DC, November 1989.
- Stensass S, Bouhaddou O, Hardy L, Sorenson D The Educational potential of linking a videodisk to an expert system. Proceedings of the 13th Symposium on Computer Applications in Medical Care. Washington DC, November 1989.
- Cundick R, Turner C, Lincoln M, Buchanan J, Anderson C, Warner H Jr, Bouhaddou O. Iliad as a patient case simulator to teach medical problem solving. Proceedings of the 13th Symposium on Computer Applications in Medical Care. Washington DC, November 1989.
- Hong Y, Haug P, Turner C. Embedding Clinical Statistics in a Data Dictionary for Use in an Expert System. Proceedings of the 13th Symposium on Computer Applications in Medical Care. Washington DC, November 1989.

- Sorenson DK, Cundick RM, Fan C, Warner HR. Passing partial information among Bayesian and Boolean frames. Proceedings of the 13th Symposium on computer Applications in Medical Care. Washington DC, November 1989.
- Ben-Said M, Dougherty Nina, Altman Stan, Anderson Curtis, Bouhaddou Omar and Warner Homer. KESS: Knowledge Engineering Support System. Proceedings of the 11th Symposium on computer Applications in Medical Care. Washington DC, November 1987. pp56-59.
- Yu H, et al. Embedding clinical statistics in a data dictionary for use in an expert system.Proceedings of the 13th Symposium on Computer Applications in Medical Care. Washington DC, November 1989.
- Lincoln M, Haug P, Yu H, Turner C, Warner H. Expert Biases Prevent Accurate Estimation of Population Statistics for Clustered Disease Frames. Proceedings of the Medical Informatics & Education International Symposium, pp 237-241, Victoria, B. C., Canada, May 15-19, 1989.
- Turner C, Lincoln M, Haug P, Warner H, Williamson J, Whitman N, Buchanan J. Clustered disease findings: aspects of expert systems. Proceedings of the Medical Informatics & Education International Symposium, pp 237-241, Victoria, B. C., Canada, May 15-19, 1989.
- Warner HR, Haug P, Bouhaddou O, Lincoln M, Warner HR Jr, Sorenson D, Williamson JW, Fan C. Iliad: An Expert Consultant to Teach Differential Diagnosis (SCAMC 88) pp371.
- Robert F Rubeck Software review. Iliad: A medical Diagnostic Expert System Teaching and Learning Medicine, 1989, vol1,N4, 221-222

Rootenberg JD, Garcia SP. An Odyssey through Iliad. JAMA 1990.

- Bouhaddou O, Lepage E. Evaluating The Transferability of a Medical Knowledge Base Between Two Different Geographical Locations. Submitted for presentation at the 14th Symposium on Computer Applications in Medical Care, Washington November 1990
- Warner HR, Bouhaddou O, Yu H, Lincoln MJ. The Knowledge Capabilities of the Vocatulary Component of a Medical Expert System. Submitted for presentation at the 14th Symposium on Computer Applications in Medical Care, Washington November 1990
- Turner CW et al. The effects of Iliad on Medical Problem-Solving. Submitted for presentation at the 14th Symposium on Computer Applications in Medical Care, Washington November 1990

Presentations:

Anderson CL, Lincoln MJ. Pathways to medical information. Information Technology in the Health Sciences Conference, Memphis, Tennessee, May 13-15, 1987.

- Haug PJ, Anderson CL. Iliad: A medical decision-making expert system. Information Technology in the Health Sciences Conference, Memphis, Tennessee, May 11-13, 1988.
- Lincoln MJ. Recent developments in knowledge representation for medical expert systems. Heidelberg '88 Apple European University Consortium. Heidelberg, West Germany, April 5-9, 1988;
- Lincoln MJ. The Iliad expert system for medicine. University of Utah Department of Pediatrics, Salt Lake City, Utah, May 20, 1988.
- Lincoln MJ. The Iliad student experiment. VA Hospital Department of Internal Medicine, Salt Lake City, Utah, September 6, 1988.
- Lincoln MJ. Iliad and knowledge base development in the Division of Internal Medicine. Division of General Internal Medicine, Salt Lake City, Utah, September 16, 1988.
- Warner HR. Iliad. American Hospital Association, Miami, Florida, February 11, 1988.
- Warner HR. Iliad. Conference of the Western Association of American Medical Colleges, Carmel, California, April 25, 1988.
- Warner HR. Iliad. Association of Medical Systems and Instrumentation, San Francisco, California, May 5, 1988.
- Warner HR. Iliad. Address to the University of Calgary Medical Faculty, Edmonton, Canada, June 9, 1988.
- Warner HR. The future of health care in America: the role of medical technology. Testimony before the U.S. Senate Joint Economic Committee, Subcommittee on Education and Health, Washington DC, May 24, 1988.
- Lincoln M. Presentation on Iliad for IAIMS Management Committee. Georgetown University, Washington, DC, October 5, 1989
- Lincoln M. Presentation on Iliad at RIME Symposium. Association of American Medical Colleges, Washington, DC, October 31, 1989.
- Warner H. Seminar on Iliad. Southern Group on Medical Education (SGME). University of North Carolina, Chapel Hill, NC, April 12, 1989.
- Warner H. Seminar on Iliad. University of Pennsylvania, Philadelphia, PA, April 13, 1989.
- Applied Informatics & Department of Medical Informatics. Iliad Conference,295 Chipeta Way, Salt Lake City, UT, July 20-21, 1989.
- Bouhaddou O. Integration between expert systems and Hospital Information Systems. Conference on Information Technology in Health Sciences. Memphis, TN May 2-4,1989.
- Warner H. Seminar on Iliad. American Medical Student Association (AMSA), March 21-23, 1990. Washington, DC.

- Bouhaddou O. Seminar on Iliad. Southern Group on Medical Education. University of North Carolina, Chapel Hill, NC, March 29-30, 1990.
- Warner HR. Seminar on Iliad. National Symposium on Computers in Medical Education. April 7-8, 1990. U. Nebraska.
- Warner HR Jr. Seminar on Iliad. American College of Physicians (ACOP). April 26-29, Chicago.
- Sorenson D. Seminar on Iliad. Central Group on Medical Education (CGME). April 26-29, 1990. Indiana University.
- Lincoln MJ and Bouhaddou O Experience with the Iliad expert system. Conference on Information Technology in Health Sciences. Memphis, TN May 2-4,1990.
- Warner H, Bouhaddou O, Yu H, Lincoln MJ. The Knowledge Capabilities of the Vocabulary Component of a Medical Expert System. 14th SCAMC, Washington november 1990
- Turner C. et al. Evaluating the impact of Iliad on medical students. 14th SCAMC, Washington november 1990.

LIST OF INVENTIONS:

No inventions were created.